AimedBio, Boehringer Ingelheim Dose First Patient in Phase I Trial of Cancer Drug BI 4060107

• AimedBio’s antibody-drug conjugate BI 4060107 entered Phase I testing with the first patient dosed; Boehringer Ingelheim is developing the treatment.
• The first-in-human study evaluates different doses in patients with advanced solid tumors, focusing on tolerability.
• The milestone triggers a payment under the companies’ October 2025 global licensing agreement.
• The agreement provides for up to $991 million in upfront and milestone payments, plus royalties on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aimed Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610262000BIZWIRE_USPR_____20261026_BW853403) on October 27, 2026, and is solely responsible for the information contained therein.